---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-22-000029"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2022-11-29T23:59:59+00:00"
generated_at: "2026-06-21T12:17:39.619368+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caribou Bio receives RMAT and Fast Track designations from FDA for CB-010 CAR-T therapy

## Summary
- FDA grants RMAT for relapsed/refractory large B cell lymphoma (LBCL) and Fast Track for r/r B-NHL for CB-010.
- CB-010 is first allogeneic anti-CD19 CAR-T with PD-1 knockout in clinic.
- In ANTLER Phase 1 trial at dose level 1: 6/6 patients (100%) achieved CR, 3/6 (50%) maintained CR at 6 months.
- Designations offer expedited development benefits: Priority Review, Rolling Review, Accelerated Approval eligibility.

## SEC filing metadata
- accession: 0001619856-22-000029
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2022-11-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000029/0001619856-22-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985622000029/crbu-20221129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-22-000029
- JSON: https://secwatch.observer/filing/0001619856-22-000029.json
- Plain text: https://secwatch.observer/filing/0001619856-22-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.